Skip to main content
. 2020 Aug 25;10(4):178–211.

Table 3.

Spectrum of Malignancies treated by PRRT with 177Lu-DOTATATE and their relative distribution

Patients characteristics Number of Patients
177Lu-DOTATATE PRRT 1000
90Y-DOTATATE PRRT 11
Site of primary disease for 1000 pts
    Gastroenteropancreatic NENs (GEP-NENs) 781
    Metastatic NEN with unknown primary (CUP-NEN) 87
    Lung NENs 30
    Mediastinal/thymus NENs 27
    Medullary Thyroid carcinoma (MTC) 50
    Pheochromocytomas and Paraganglioma (PCC/PGL) 15
    Miscellaneous 10